All In Biotech

Drug Trial Radar · NCT07529808

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

164

Planned (sponsor's estimate)

Start

Jul 16, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
BigHat Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Apr 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.

Conditions

  • Gastric Cancer
  • Gastric Adenocarcinoma
  • Gastric (Stomach) Cancer
  • Gastroesophageal Adenocarcinoma
  • Gastroesophageal Cancer (GC)
  • Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Gastroesophageal Junction (GEJ) Cancer
  • Gastrointestinal Cancer Metastatic
  • Gastrointestinal Adenocarcinoma
  • Gastrointestinal Cancers
  • Colorectal (Colon or Rectal) Cancer
  • Pancreatic Cancer
  • CDH17-positive Advanced Solid Tumors
  • Advanced Gastric Cancer

Interventions

  • BHB810Drug

    Every 2 weeks IV administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) per Common Terminology Criteria for Adverse Events v6.0 (CTCAE v6.0)Time frame: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
  2. Incidence of participants who have a dose modification of BHB810 due to toxicityTime frame: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
  3. Overall Response Rate (ORR)Time frame: Screening through End of Treatment, an average of 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Duarte

    Duarte, California · Recruiting

  • University of California at Los Angeles

    Santa Monica, California · Not yet recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.